广东医学2012，Vol.33Issue(20)：3144-3146,3.
两种阿德福韦酯片治疗慢性乙型肝炎96周的疗效和安全性比较
Comparisons of efficacy and safety between two kinds of adefovir dipivoxil (Daiding and Hepsera) on treament of chronic hepatitis B
揭育胜 1吴元凯 1李向永 1熊庭婷 1张秀娟 1敖云龙 1崇雨田1
作者信息
- 1. 中山大学附属第三医院感染科,广州510630
- 折叠
摘要
Abstract
Objective To compare the efficacy and safety between two kinds of adefovir dipivoxil (Dai ding and Hepsera) on treatment of chronic hepatitis B (CHB). Methods A total of 122 patients in clinic with CHB were enrolled and divided into Daiding group (n =66) and Hepsera group (n =56) , in which the age, gender, serum alanine amin-otransferase ( ALT) , HBV DNA and HBeAg status were matched. Serum ALT level, HBV DNA drop, HBeAg clearance, rates of undetected HBV DNA and drug adverse reactions were analyzed at the time of 24, 48 and 96 weeks. Results The rates of ALT normalization, HBV DNA drop, HBeAg clearance and undetected DNA were increased along with antiviral therapy prolonged in both groups, with no significant difference between them (P >0. 05). At the 96'1' week, the cumulative rates of viral breakthrough were 13.6% (9/66) and 16. 1% (9/56) in Daiding group and Hepsera group, respectively , with no significant difference revealed ( P > 0. 05 ) . No adverse event was reported. Conclusion Two kinds of adefovir dipivoxil ( Daiding and Hepsera) are effective in improving liver function and suppressing HBV replication, with good safety for patients with CHB. There are no significant difference in the efficacy and safety in 96 - week follow - up.
关键词
乙型肝炎病毒/阿德福韦酯/疗效/安全性Key words
hepatitis B virus/ adefovir dipivoxil/ efficacy/ safety引用本文复制引用
揭育胜,吴元凯,李向永,熊庭婷,张秀娟,敖云龙,崇雨田..两种阿德福韦酯片治疗慢性乙型肝炎96周的疗效和安全性比较[J].广东医学,2012,33(20):3144-3146,3.
